Impact of DOTS and DOTS-plus on multidrug resistant TB: Authors' replyBMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7407.164-a (Published 17 July 2003) Cite this as: BMJ 2003;327:164
- Timothy R Sterling (firstname.lastname@example.org), associate professor of medicine,
- Harold P Lehmann, associate professor,
- Thomas R Frieden, commissioner of health
- Vanderbilt University Medical Center, 1161 21st Avenue South, A4103 Medical Center North, Nashville, TN 37232-2605, USA
- Department of Health Sciences Information, Johns Hopkins University School of Medicine, 2024 E Monument Street, Baltimore, MD 21287-0007, USA
- New York City Department of Health, 125 Worth Street, New York, NY 10013, USA
EDITOR—Health systems have limited budgets and capacity so resources for DOTS-plus may be unavailable for DOTS (directly observed treatment, short course), which can reduce programme effectiveness. Lack of financial and human resources are primary reasons for the current low global implementation rate of DOTS.
Mitnick et al provide encouraging results, although they reported on only 75 of 731 (10%) of the cases of multidrug resistant tuberculosis referred for evaluation.1 Knowing the effectiveness …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial